EPO Biomarkers Market size and Key Trends in terms of volume and value 2016-2026
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>EPO</strong> <strong>Biomarkers</strong><br />
<strong>Market</strong><br />
Share, Global <strong>Trends</strong>,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation <strong>and</strong> Forecast,<br />
<strong>2016</strong><br />
Future <strong>Market</strong> Insights<br />
www.futuremarket<strong>in</strong>sights.com<br />
sales@futuremarket<strong>in</strong>sights.com
Future <strong>Market</strong> Insights (FMI) is a premier provider <strong>of</strong> syndicated research reports, custom research reports, <strong>and</strong> consult<strong>in</strong>g<br />
services. We deliver a complete packaged solution, which comb<strong>in</strong>es current market <strong>in</strong>telligence, statistical anecdotes,<br />
technology <strong>in</strong>puts, valuable growth <strong>in</strong>sights, aerial view <strong>of</strong> the competitive framework, <strong>and</strong> future market trends.<br />
We provide research services at a global as well as regional level; key regions <strong>in</strong>clude GCC, ASEAN, <strong>and</strong> BRIC.<br />
Our <strong>of</strong>fer<strong>in</strong>gs cover a broad spectrum <strong>of</strong> <strong>in</strong>dustries <strong>in</strong>clud<strong>in</strong>g Chemicals, Materials, Energy, Technology, Healthcare, <strong>and</strong><br />
Retail.<br />
We have a global presence with delivery centers across India specializ<strong>in</strong>g <strong>in</strong> provid<strong>in</strong>g global research reports <strong>and</strong> country<br />
research reports. FMI is headquartered out <strong>of</strong> London, U.K., with a state-<strong>of</strong>-the-art delivery center located <strong>in</strong> Pune, India.<br />
We comb<strong>in</strong>e our knowledge <strong>and</strong> learn<strong>in</strong>g from every corner <strong>of</strong> the world to distill it to one th<strong>in</strong>g – the perfect solution for<br />
our client.<br />
Research Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Sector Coverage<br />
• Automotive <strong>and</strong> Transportation<br />
• Electronics, Semiconductor, <strong>and</strong> ICT<br />
• Retail <strong>and</strong> Consumer Products<br />
• Industrial Automation <strong>and</strong> Equipment<br />
• Chemicals & Materials<br />
• Food <strong>and</strong> Beverages<br />
• Services <strong>and</strong> Utilities<br />
• Energy, M<strong>in</strong><strong>in</strong>g, Oil, <strong>and</strong> Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription <strong>in</strong>formation please contact<br />
Hari. T (Sr. Manager - Global Bus<strong>in</strong>ess Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarket<strong>in</strong>sights.com
Report Description<br />
Erythropoiet<strong>in</strong> is special type <strong>of</strong> prote<strong>in</strong> biomarker, also known as a growth factor. It acts<br />
by the stimulat<strong>in</strong>g the bone marrow to manufacture red blood cells. There are five<br />
different types <strong>of</strong> erythropoiet<strong>in</strong> biomarkers such as epoet<strong>in</strong> alfa, epoet<strong>in</strong> beta, epoet<strong>in</strong><br />
zeta, epoet<strong>in</strong> theta <strong>and</strong> darbepoet<strong>in</strong> alfa. Erythropoiet<strong>in</strong> is mostly adm<strong>in</strong>istered<br />
subcutaneously as an alternative to iron supplements. Erythropoiet<strong>in</strong> used <strong>in</strong> human<br />
be<strong>in</strong>gs is also known as recomb<strong>in</strong>ant human erythropoiet<strong>in</strong> (rHu<strong>EPO</strong>). Commercially<br />
available rHu<strong>EPO</strong> has the same 165 am<strong>in</strong>o acid sequence as available <strong>in</strong> naturally<br />
occurr<strong>in</strong>g hormone but the level <strong>of</strong> glycosylation <strong>in</strong> rHu<strong>EPO</strong> depends on the test<strong>in</strong>g<br />
method used. Grow<strong>in</strong>g global <strong>in</strong>cidence <strong>of</strong> renal diseases <strong>and</strong> cancers is expected to<br />
create a marked <strong>in</strong>crease <strong>in</strong> use <strong>of</strong> <strong>EPO</strong> biomarkers.<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: Drivers & Restra<strong>in</strong>ts<br />
The prime drivers for the market <strong>in</strong>clude grow<strong>in</strong>g <strong>in</strong>cidence <strong>of</strong> cancers <strong>and</strong> renal diseases.<br />
Changes <strong>in</strong> lifestyle <strong>and</strong> improper eat<strong>in</strong>g habits contribute to pancreatic <strong>and</strong> endocr<strong>in</strong>e<br />
cancers, which <strong>of</strong>ten lead to severe anaemia, where external erythropoiet<strong>in</strong> <strong>in</strong>fusion is<br />
required. Other drivers for the <strong>EPO</strong> biomarker market is technological advancement <strong>in</strong><br />
devis<strong>in</strong>g proprietary test<strong>in</strong>g methods apart from tried <strong>and</strong> tested ones.<br />
Restra<strong>in</strong>ts for the market <strong>in</strong>clude lack <strong>of</strong> availability <strong>of</strong> skilled labour <strong>and</strong> sufficient quality<br />
controlled test<strong>in</strong>g laboratories <strong>in</strong> most countries <strong>in</strong> less developed regions. Insufficient<br />
R&D <strong>in</strong> identification <strong>of</strong> biomarkers due to adoption <strong>of</strong> cost cutt<strong>in</strong>g measures <strong>in</strong> European<br />
regions is expected to restra<strong>in</strong> proper quantitative assessment <strong>of</strong> drugs <strong>and</strong> their<br />
therapeutic efficacy <strong>in</strong> blood.
Report Description<br />
This could also hamper progress <strong>of</strong> ongo<strong>in</strong>g cl<strong>in</strong>ical trials <strong>and</strong> proper stratification <strong>of</strong><br />
patients.<br />
Request free sample Report: http://www.futuremarket<strong>in</strong>sights.com/reports/sample/repgb-1382<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: Segmentation<br />
<strong>EPO</strong> <strong>Biomarkers</strong> is classified on the basis <strong>of</strong> biomarker, <strong>in</strong>dication, test<strong>in</strong>g method <strong>and</strong><br />
end user type:<br />
Based on biomarker type, the global <strong>EPO</strong> <strong>Biomarkers</strong> is segmented <strong>in</strong>to the follow<strong>in</strong>g:<br />
• Recomb<strong>in</strong>ant human erythropoiet<strong>in</strong><br />
• Erythropoiet<strong>in</strong> alfa<br />
• Erythropoiet<strong>in</strong> beta<br />
• Erythropoiet<strong>in</strong> zeta<br />
• Erythropoiet<strong>in</strong> theta<br />
• Darbepoiet<strong>in</strong> alfa<br />
Based on <strong>in</strong>dication, the global <strong>EPO</strong> <strong>Biomarkers</strong> is segmented <strong>in</strong>to follow<strong>in</strong>g:<br />
• End stage renal disorder
Report Description<br />
• Cancers<br />
• Rheumatoid arthritis<br />
• AIDS<br />
• Others<br />
Based on end users, the global <strong>EPO</strong> <strong>Biomarkers</strong> is segmented <strong>in</strong>to the follow<strong>in</strong>g:<br />
• Diagnostic centers<br />
• Hospitals<br />
• Ambulatory care <strong>and</strong> surgical centers<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: Overview<br />
<strong>EPO</strong> biomarker market is account to rise <strong>in</strong> <strong>value</strong> dur<strong>in</strong>g the forecast period. Due to<br />
expansion <strong>in</strong> the product segment <strong>of</strong> <strong>EPO</strong> biomarkers the market share will be ris<strong>in</strong>g with<br />
a promis<strong>in</strong>g rate, also with the <strong>in</strong>crease <strong>in</strong> dem<strong>and</strong> for diagnosis <strong>and</strong> treatment <strong>of</strong> widely<br />
spread chronic disease the <strong>EPO</strong> market is expected to grow with a promis<strong>in</strong>g CAGR dur<strong>in</strong>g<br />
the forecast period. Biologic drug <strong>in</strong>dustry is <strong>in</strong>vest<strong>in</strong>g on R&D <strong>and</strong> the key players are<br />
focus<strong>in</strong>g on <strong>in</strong>creas<strong>in</strong>g their production capacity for <strong>EPO</strong> biomarkers.<br />
Request for TOC: http://www.futuremarket<strong>in</strong>sights.com/toc/rep-gb-1382
Report Description<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: Region-wise Outlook<br />
Consider<strong>in</strong>g all potential geographic regions, <strong>EPO</strong> biomarkers market is segmented <strong>in</strong>to<br />
seven key regions: North America, Lat<strong>in</strong> America, Eastern Europe, Western Europe,<br />
Japan, Asia Pacific <strong>and</strong> Middle East & Africa. North America is been dom<strong>in</strong>at<strong>in</strong>g <strong>in</strong> the<br />
<strong>EPO</strong> biomarkers due to rise <strong>in</strong> acceptance for bio-similar weakly followed by Western <strong>and</strong><br />
Eastern Europe, Asia Pacific has a dom<strong>in</strong>at<strong>in</strong>g presence <strong>in</strong> <strong>EPO</strong> biomarker market <strong>and</strong><br />
most <strong>of</strong> the key players are locally produc<strong>in</strong>g the <strong>EPO</strong> biomarkers, that is enhanc<strong>in</strong>g their<br />
market share <strong>and</strong> product reach. There is a good opportunity for Japan <strong>in</strong> <strong>EPO</strong><br />
biomarker market. The emerg<strong>in</strong>g regions <strong>in</strong> Asia Pacific, Middle East <strong>and</strong> Africa holds<br />
promis<strong>in</strong>g future for rise <strong>in</strong> <strong>EPO</strong> biomarker market, due to <strong>in</strong>crease <strong>in</strong> awareness towards<br />
the chronic disease <strong>and</strong> <strong>in</strong>crease <strong>in</strong> population simultaneously.<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: <strong>Key</strong> Players<br />
Sh<strong>and</strong>ong Kex<strong>in</strong>g Bioproducts Co., Ltd., Amgen Inc., Ranbaxy Laboratories Ltd, Johnson &<br />
Johnson, Roche Hold<strong>in</strong>g AG, Sigma-Aldrich, Thermo Fisher Scientific, Hospira Inc., Biocon,<br />
Teva Pharmaceutical Industries Ltd.,<br />
Browse full report: http://www.futuremarket<strong>in</strong>sights.com/reports/epo-biomarkersmarket
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarket<strong>in</strong>sights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarket<strong>in</strong>sights.com<br />
For other queries contact: Mr. Sudip Saha<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705
Change language